Telomir Pharmaceuticals, Inc. has released in vitro data demonstrating that its lead candidate, Telomir-1, effectively inhibits three critical histone demethylase enzymes—JMJD3, FBXL10, and FBXL11—known to regulate gene expression and implicated in a range of conditions including cancer, autoimmune disorders, neurodegeneration, and metabolic dysfunction.
The company said that the study, conducted with Eurofins Discovery, highlights Telomir-1’s potential to address disease by modulating epigenetic mechanisms. Telomir-1 was shown to outperform established agents such as paclitaxel and rapamycin in preclinical cancer models, particularly through reactivating tumor suppressor genes.
The company claims these findings support the continued preclinical development of Telomir-1 as a broadly applicable therapeutic, and said that it is advancing toward first-in-human testing via an upcoming IND-enabling program.
This development underscores Telomir’s strategy of targeting foundational epigenetic drivers across multiple high-need indications, potentially positioning Telomir-1 as a multi-disease platform therapy advancing toward clinical translation.
